Tags

Type your tag names separated by a space and hit enter

Sodium oxybate for cataplexy.
Ann Pharmacother. 2006 Mar; 40(3):433-40; quiz 581-2.AP

Abstract

OBJECTIVE

To review the pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, precautions, dosing recommendations, and patient counseling of sodium oxybate for the treatment of cataplexy in patients with narcolepsy.

DATA SOURCES

OVID and PubMed databases were searched (1966-January 2006) using the key words sodium oxybate, gamma-hydroxybutyrate, narcolepsy, and cataplexy. Only English-language articles were selected.

STUDY SELECTION AND DATA EXTRACTION

All information on sodium oxybate related to narcolepsy and cataplexy was considered. Study selection included human trials evaluating safety and efficacy of sodium oxybate for the treatment of cataplexy.

DATA SYNTHESIS

Sodium oxybate is approved by the Food and Drug Administration for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy. In placebo-controlled trials, sodium oxybate demonstrated efficacy in reducing the number of cataplexy attacks. The dosing regimen includes a split dose given at bedtime and 2.5-4 hours later due to its short elimination half-life. The drug is generally well tolerated, with headache, nausea, dizziness, pain, and somnolence being the most common adverse events.

CONCLUSIONS

Sodium oxybate is safe and effective for the treatment of cataplexy. Potential disadvantages include a multiple dosing regimen, abuse potential, cost, and a closed distribution system. Potential advantages demonstrated in clinical trials include significant decreases in the number of weekly cataplexy attacks, improvement in daytime sleepiness, and improvement in the Clinical Global Impression of Change score and nighttime awakenings. Overall, sodium oxybate provides a new option for the treatment of cataplexy.

Authors+Show Affiliations

College of Pharmacy, South Dakota State University; Veterans Affairs Black Hills Health Care System, Fort Meade, 57741, USA. Michael.lemon@med.va.govNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16507620

Citation

Lemon, Michael D., et al. "Sodium Oxybate for Cataplexy." The Annals of Pharmacotherapy, vol. 40, no. 3, 2006, pp. 433-40; quiz 581-2.
Lemon MD, Strain JD, Farver DK. Sodium oxybate for cataplexy. Ann Pharmacother. 2006;40(3):433-40; quiz 581-2.
Lemon, M. D., Strain, J. D., & Farver, D. K. (2006). Sodium oxybate for cataplexy. The Annals of Pharmacotherapy, 40(3), 433-40; quiz 581-2.
Lemon MD, Strain JD, Farver DK. Sodium Oxybate for Cataplexy. Ann Pharmacother. 2006;40(3):433-40; quiz 581-2. PubMed PMID: 16507620.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Sodium oxybate for cataplexy. AU - Lemon,Michael D, AU - Strain,Joe D, AU - Farver,Debra K, Y1 - 2006/02/28/ PY - 2006/3/2/pubmed PY - 2006/4/28/medline PY - 2006/3/2/entrez SP - 433-40; quiz 581-2 JF - The Annals of pharmacotherapy JO - Ann Pharmacother VL - 40 IS - 3 N2 - OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, precautions, dosing recommendations, and patient counseling of sodium oxybate for the treatment of cataplexy in patients with narcolepsy. DATA SOURCES: OVID and PubMed databases were searched (1966-January 2006) using the key words sodium oxybate, gamma-hydroxybutyrate, narcolepsy, and cataplexy. Only English-language articles were selected. STUDY SELECTION AND DATA EXTRACTION: All information on sodium oxybate related to narcolepsy and cataplexy was considered. Study selection included human trials evaluating safety and efficacy of sodium oxybate for the treatment of cataplexy. DATA SYNTHESIS: Sodium oxybate is approved by the Food and Drug Administration for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy. In placebo-controlled trials, sodium oxybate demonstrated efficacy in reducing the number of cataplexy attacks. The dosing regimen includes a split dose given at bedtime and 2.5-4 hours later due to its short elimination half-life. The drug is generally well tolerated, with headache, nausea, dizziness, pain, and somnolence being the most common adverse events. CONCLUSIONS: Sodium oxybate is safe and effective for the treatment of cataplexy. Potential disadvantages include a multiple dosing regimen, abuse potential, cost, and a closed distribution system. Potential advantages demonstrated in clinical trials include significant decreases in the number of weekly cataplexy attacks, improvement in daytime sleepiness, and improvement in the Clinical Global Impression of Change score and nighttime awakenings. Overall, sodium oxybate provides a new option for the treatment of cataplexy. SN - 1060-0280 UR - https://www.unboundmedicine.com/medline/citation/16507620/Sodium_oxybate_for_cataplexy_ L2 - https://journals.sagepub.com/doi/10.1345/aph.1G456?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -